FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 01/2025”.
The Monitor is a month-to-month printed overview of enterprise capital tendencies within the US Healthcare & Life Sciences sector.
As of the tip of January 2025 we recognized the next present VC tendencies in the USA:
- Whole Healthcare & Life Sciences funding reached EUR 4,388m
- Biotech/Pharma acquired 53% of the entire funding quantity (EUR 2,321m) with immunology being the main indication (27%)
- In January Truveta secured the highest transaction quantity with EUR 307m, adopted by Kardigan with EUR 288m and Innovaccer with EUR 264m
- Accelmed (United States) is essentially the most lively investor (by deal quantity in 2025), adopted by Y Combinator (United States) and F-Prime Capital (United States)
To entry the total report, please click on right here.
